(Z)-Ligustilide

(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6^[1]. (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) ^[2]. (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer^[3]. In Vitro:Z-ligustilide (25 and 100 µM, 24 hours) can effectively inhibit oleic acid-induced lipid accumulation in HepG2 cells, suppress fatty acid uptake and esterification, and has potential anti-fatty liver effects^[2].
Z-ligustilide (10-50 μM, 72 hours) can significantly enhance the sensitivity of ERα-negative breast cancer cells to Tamoxifen (HY-13757A) by restoring the expression of ERα^[3]. In Vivo:Z-ligustilide (50 mg/kg, p.o., once daily for 6 weeks) significantly reduces hepatic lipid accumulation in high-fat diet-induced fatty liver mice, inhibiting fatty acid uptake and esterification, demonstrating potential application value for non-alcoholic fatty liver disease (NAFLD)^[2].